JZYY(SH:600750)2023-04-26 16:00Financial Position - The total assets of the company amount to 6,316,949,481.06 yuan, an increase from 6,243,659,088.84 yuan in the previous period[10]. - The company reported a total of 1,473,621,799.63 yuan in current liabilities, a decrease from 1,657,669,253.49 yuan in the previous period[10]. - The company has a total of 138.5 million yuan in other non-current financial assets[10]. - The total liabilities decreased to ¥1,561,109,382.72 from ¥1,748,281,711.63, indicating improved financial stability[50]. - Equity attributable to shareholders increased by 6.25% to ¥4,134,244,495.15 from ¥3,890,966,277.28[37]. Cash Flow - The company's cash and cash equivalents at the end of the period are 492,765,197.35 yuan, down from 550,324,166.65 yuan at the beginning of the period, resulting in a net decrease of 57,558,969.30 yuan[15]. - Operating cash inflow totaled $1,239,030,198.30, an increase from $751,780,919.26 in the previous period[71]. - Operating cash outflow amounted to $1,177,138,767.46, compared to $771,340,336.36 previously, resulting in a net cash flow from operating activities of $61,891,430.84, up from a negative $19,559,417.10[71]. - Investment cash inflow was $763,779,065.02, down from $864,376,241.00 in the prior period[71]. - Investment cash outflow reached $883,229,465.16, compared to $679,966,641.72 previously, leading to a net cash flow from investing activities of -$119,450,400.14, down from $184,409,599.28[71]. - The company received tax refunds amounting to $21,567,303.42[71]. - Cash received from other operating activities was $39,269,633.66, compared to $19,211,152.76 previously[71]. - Total cash paid for taxes was $157,140,068.85, up from $74,980,014.68[71]. Revenue and Profitability - The company's operating revenue for Q1 2023 reached ¥1,316,378,726.66, representing a year-on-year increase of 41.44%[20]. - The net profit attributable to shareholders of the listed company was ¥240,831,060.77, up 31.10% compared to the same period last year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥224,783,546.46, reflecting a 29.61% increase year-on-year[20]. - The basic earnings per share for the period was ¥0.38, which is a 31.03% increase from the previous year[20]. - The gross profit margin for over-the-counter drugs was 72.80%, an increase of 3.41 percentage points compared to the same period last year[24]. - The revenue from the health products and others segment surged by 184.66% year-on-year, although the gross profit margin decreased to 33.15%[24]. - Revenue from the East China region increased by 83.65% year-on-year, amounting to ¥459,336,359.19[24]. - The gross margin for the pharmaceutical industry was 67.97%, a decrease of 0.99 percentage points year-on-year[37]. - The company reported a decrease in the gross margin for health products and others, primarily due to changes in product revenue structure[39]. Expenses and Investments - The company's total operating costs for Q1 2023 were CNY 1,034,301,889.35, compared to CNY 721,704,291.98 in Q1 2022, marking an increase of around 43.4%[70]. - Research and development expenses for Q1 2023 amounted to CNY 26,642,289.45, slightly down from CNY 27,972,879.52 in Q1 2022[70]. - The company's sales expenses for Q1 2023 were CNY 531,495,354.11, up from CNY 353,212,883.66 in Q1 2022, indicating an increase of approximately 50.6%[70]. - The tax expenses for Q1 2023 were CNY 46,598,116.68, compared to CNY 36,263,791.67 in Q1 2022, reflecting an increase of about 28.6%[70]. - The investment income for Q1 2023 showed a loss of CNY 350,858.42, compared to a gain of CNY 1,189,302.97 in Q1 2022[70]. Legal and Other Matters - As of the reporting period, the company has a remaining overdue principal of 6.75 million yuan from entrusted loans to Changrong Automobile, with legal actions ongoing[4]. - The company has initiated a lawsuit against Changrong Automobile and related guarantors to recover overdue loans[4]. - The company has plans for future entrusted financial management, indicating ongoing investment strategies[5]. - The company has a total of 3,100,000 shares held through margin accounts by its representative, Luo Jun[3]. - The total number of ordinary shareholders at the end of the reporting period was 35,551[27].